Home > Patients > Current Clinical Trials

Current Clinical Trials

NovaDigm is conducting a clinical trial of its NDV-3A vaccine in 420 military recruits, who are at high risk for skin and soft tissue infections (SSTIs) due to S. aureus. About 30% of military recruits are colonized with S. aureus in their nasal passages upon arrival at basic training and many more acquire colonization during training.  Those who are colonized are at increased risk for SSTIs.  The main purpose of this study is to assess the impact of a single dose of NDV-3A on preventing acquisition of S. aureus colonization during the training period in those not colonized at the beginning of training, with a secondary purpose of evaluating the impact of the vaccine in decreasing S. aureus colonization in those already colonized at the beginning of training.  If successful, a larger study would be conducted with prevention of SSTIs as an endpoint. Safety, tolerability and immunogenicity of the vaccine in this population is also being evaluated. To find out more about this study, please see the clinicaltrials.gov entry for study NCT03455309 and see our press release.